featured
Vemurafenib Plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Vemurafenib Plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
N. Engl. J. Med 2021 May 13;384(19)1810-1823, E Tiacci, L De Carolis, E Simonetti, M Capponi, A Ambrosetti, E Lucia, A Antolino, A Pulsoni, S Ferrari, PL Zinzani, S Ascani, VM Perriello, L Rigacci, G Gaidano, R Della Seta, N Frattarelli, P Falcucci, R Foà, G Visani, F Zaja, B FaliniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.